Citigroup
FMTX

Citigroup’s Forma Therapeutics Holdings, Inc. Common Stock FMTX Stock Holding History

Citigroup’s Portfolio FMTX Stock Details FMTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,955
Closed -$39K – 6197
2022
Q3 		$39K Sell
1,955
-3,769
-66% -$49.7K ﹤0.01% 4503
2022
Q2 		$39K Sell
5,724
-22,093
-79% -$155K ﹤0.01% 4657
2022
Q1 		$259K Sell
27,817
-70,627
-72% -$752K ﹤0.01% 3920
2021
Q4 		$1.4M Buy
98,444
+59,491
+153% +$1.03M ﹤0.01% 2926
2021
Q3 		$903K Sell
38,953
-108,577
-74% -$2.57M ﹤0.01% 3161
2021
Q2 		$3.67M Buy
147,530
+29,387
+25% +$790K ﹤0.01% 2180
2021
Q1 		$3.31M Buy
118,143
+113,370
+2,375% +$4.09M ﹤0.01% 2120
2020
Q4 		$167K Buy
4,773
+3,999
+517% +$174K ﹤0.01% 5127
2020
Q3 		$39K Buy
+774
New +$31.3K ﹤0.01% 5757

Citigroup's FMTX Position: Q4 2022 in Review

Citigroup sold out of Forma Therapeutics Holdings, Inc. Common Stock (FMTX) in Q4 2022, closing a stake of 1,955 shares — an estimated $39K sold.

Citigroup first reported a position in FMTX in Q3 2020 and held it in 9 quarters. The position peaked at $3.67M in Q2 2021. 0 funds tracked by Wall St. Rank hold FMTX as of Q4 2022.

  • Citigroup reported no remaining Forma Therapeutics Holdings, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Citigroup sold 1,955 Forma Therapeutics Holdings, Inc. Common Stock shares in Q4 2022, an estimated $39K.
  • Citigroup first reported a position in Forma Therapeutics Holdings, Inc. Common Stock in Q3 2020 and held it in 9 quarters.
  • Citigroup's Forma Therapeutics Holdings, Inc. Common Stock position peaked at $3.67M in Q2 2021.
  • 0 funds tracked by Wall St. Rank held Forma Therapeutics Holdings, Inc. Common Stock as of Q4 2022.

Based on Citigroup's 13F filing for Q4 2022, filed 9 Feb 2023.